At its meeting on 20 February 2023, the Transparency Council adopted Position No. 18/2023 on the evaluation of the medicine Saphnelo (anifrolumab) under th drug programme “Treatment of patients with active systemic lupus erythematosus (SLE) (ICD 10: M32)”.